Volume 22, Number 6—June 2016
MERS-CoV Antibodies in Humans, Africa, 2013–2014
|County||No. samples tested||No. (%) positive by rELISA||No. (%) positive by rELISA and with >50% plaque reduction at 1:20 dilution|
|Tana River||563||12 (2.13)||2 (0.36)|
|Total||1,122||16 (1.43)||2 (0.18)|
*rELISA, recombinant ELISA.
1These authors contributed equally to this article.
Page created: May 16, 2016
Page updated: May 16, 2016
Page reviewed: May 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.